Looking to enhance your portfolio with high-growth, financially-robust stocks, but not sure where you should even begin? Stocks such as Regis Healthcare and Factor Therapeutics are deemed to be superior in terms of how much they’re expected to earn and return to shareholders, according to analysts. Analysing the most recent financial data, I’ve created a list of companies that compare favourably in all criteria, making them potentially good additions to your portfolio.

Regis Healthcare Limited (ASX:REG)

Regis Healthcare Limited provides residential aged care services in Australia. The company size now stands at 3834 people and has a market cap of AUD A$1.10B, putting it in the small-cap category.

Driven by the positive double-digit sales growth of 15.38% over the next few years, REG is expected to deliver an excellent earnings growth of 10.67%. It appears that REG’s profitability may be sustainable as the fundamental push is top-line expansion rather than unmaintainable cost-cutting activities. This prospective profitability should trickle down to shareholders, with analysts expecting the company to generate a high double-digit return on equity of 34.94%. REG’s impressive outlook on all aspects makes it a worthy company to spend more time to understand. Want to know more about REG? Take a look at its other fundamentals here.

Factor Therapeutics Limited (ASX:FTT)

Factor Therapeutics Limited, a clinical stage biotechnology company, develops and commercializes treatments for wound care and healing in Australia and Europe. Factor Therapeutics is currently run by Rosalind Wilson. With a current market cap of AUD A$29.20M, we can put FTT in the small-cap category

An outstanding doubling of earnings is forecasted for FTT, driven by strong underlying sales growth over the next few years. It appears that FTT’s profitability may be sustainable as the fundamental push is top-line expansion rather than unmaintainable cost-cutting activities. We see this bottom-line expansion directly benefiting shareholders, with expected positive return on equity of 18.45%. FTT’s bullish prospects on both the top and bottom lines make it an interesting stock to invest more time to understand how it can add value to your portfolio. Want to know more about FTT? Take a look at its other fundamentals here.

Bellamy’s Australia Limited (ASX:BAL)

Bellamy’s Australia Limited produces and markets organic foods and formula products for babies, toddlers, and young children. Formed in 2004, and now led by CEO Andrew Cohen, the company currently employs 46 people and with the company’s market cap sitting at AUD A$2.25B, it falls under the mid-cap stocks category.